GlobalData on MSN19h
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticariaThe FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
The partners are hoping the same rapid development and deployment demonstrated with their COVID-19 vaccine Comirnaty ... should also reach the clinic this year. Sanofi has reported positive ...
Covid-19 cases have risen since last week as experts warn New Zealand's pandemic model is out of date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback